SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
450.50    16.00 (3.68%)
Bid:
449.50
Ask:
451.50
Spread: 2.00 (0.445%)
Market Cap: £221.56m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Q3 Trading Update

3 Nov 2021 07:00

RNS Number : 1247R
Zotefoams PLC
03 November 2021
 

Zotefoams plc

("Zotefoams" or the "Group")

 

Q3 Trading Update

 

3 November 2021 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the third quarter of its financial year ending 31 December 2021 ("Q3 2021").

 

Zotefoams is pleased to report a record third-quarter sales performance, with revenues approximately 11% ahead of Q3 2020 and approximately 35% ahead of Q3 2019. Excluding the significant non-repeating sales of polyolefin foams for personal protective equipment ("PPE") in 2020, Q3 2021 sales increased by approximately 54% compared to Q3 2020.

 

Demand for polyolefin foams has rebounded strongly in most markets, augmented by previously implemented price increases becoming fully effective in the third quarter. Within HPP, sales of footwear products have continued at approximately the same rate as the first half of 2021 but have been negatively impacted by the well-publicised COVID-related shutdown of our customer in Vietnam. Sales of other High-Performance Products were also significantly above the low levels of demand experienced in Q3 2020, with the result that total Q3 2021 HPP sales were up 75% year-on-year.

 

The development and early-stage commercialisation discussions of our ReZorce® mono-material barrier technology continues to meet expectations and we look forward to providing further details of this key initiative with the announcement of the full year results.

 

As previously communicated, the cost base of the business has increased, in part due to the start-up of our Poland facility but also due to commodity polymer price movements, general inflationary cost increases and additional costs incurred in managing current supply chain disruptions and inefficiency. We do not foresee a relaxation in cost pressure in the short to medium term.

 

We have good visibility of confirmed orders for the remainder of 2021 other than for T-FIT® insulation products, where orders are typically not confirmed until shortly before shipment and the project-based environment is more uncertain. Based on our sales forecasts and current foreign exchange rates, and subject to there being no additional material disruption to the business as a result of the ongoing supply chain challenges, the Board expects full-year revenues and profit before tax to be in line with market expectations.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said:

"We have been greatly encouraged by the return of strong underlying demand across most of our industry segments, although continued COVID and supply chain disruption has hampered markets such as automotive, aviation and footwear products. I am pleased that Zotefoams continues to manage this challenging environment of supply chain disruption and cost inflation well, once again demonstrating the resilience and flexibility of our people and our broad customer base. This strong commercial momentum and resilience in operational performance and cash generation gives us confidence to continue to invest for the future in all business units, with ReZorce in particular offering the potential of a very significant opportunity in the years to come"

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

 

 

 

 

 

IFC Advisory

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBTBRTMTBMBRB
Date   Source Headline
3rd May 201112:54 pmRNSTotal Voting Rights
13th Apr 20115:01 pmRNSNotice of AGM
4th Apr 201111:04 amRNSDirector/PDMR Shareholding
31st Mar 20113:04 pmRNSDirector/PDMR Shareholding
31st Mar 20117:00 amRNSAcquisition of MuCell and Share Placing
23rd Mar 20113:24 pmRNSDirector/PDMR Shareholding
8th Mar 20117:00 amRNSFinal Results
14th Feb 20113:47 pmRNSHolding(s) in Company
4th Jan 20113:00 pmRNSHolding(s) in Company
22nd Dec 20103:49 pmRNSHolding(s) in Company
21st Dec 20107:00 amRNSTrading Statement
16th Dec 201012:11 pmRNSHolding(s) in Company
2nd Dec 20109:32 amRNSDirectorate Change
17th Nov 20103:55 pmRNSHolding(s) in Company
17th Nov 20103:52 pmRNSHolding(s) in Company
12th Nov 20103:05 pmRNSDirector/PDMR Shareholding
22nd Oct 20107:00 amRNSInterim Management Statement
22nd Oct 20107:00 amRNSInterim Management Statement
12th Oct 20108:14 amRNSHolding(s) in Company
28th Sep 20105:41 pmRNSHolding(s) in Company
28th Sep 20105:39 pmRNSHolding(s) in Company
28th Sep 20101:00 pmRNSHolding(s) in Company
27th Sep 20103:02 pmRNSHolding(s) in Company
11th Aug 201010:57 amRNSHolding(s) in Company
9th Aug 20103:27 pmRNSHolding(s) in Company
3rd Aug 20107:00 amRNSHalf Yearly Report
1st Jul 20107:00 amRNSTrading Statement
9th Jun 201012:24 pmRNSHolding in company - amendment
9th Jun 201010:32 amRNSHolding(s) in Company
28th May 20103:31 pmRNSAnnual Information Update
17th May 20107:00 amRNSDirector/PDMR Shareholding
13th May 20103:00 pmRNSResult of AGM
11th May 20107:00 amRNSAGM Statement
7th May 20104:06 pmRNSDirector/PDMR Shareholding
12th Apr 20107:00 amRNSNotice of AGM
7th Apr 20104:30 pmRNSDirector/PDMR Shareholding
29th Mar 20108:50 amRNSHolding(s) in Company
24th Mar 201012:46 pmRNSHolding(s) in Company
23rd Mar 20102:40 pmRNSDirector/PDMR Shareholding
15th Mar 20104:52 pmRNSDirector/PDMR Shareholding
9th Mar 20107:00 amRNSFinal Results
3rd Mar 20102:36 pmRNSHolding(s) in Company
10th Dec 20092:30 pmRNSTrading Statement
23rd Oct 20097:00 amRNSInterim Management Statement
9th Oct 20093:08 pmRNSHolding(s) in Company
8th Sep 20092:13 pmRNSHolding(s) in Company
18th Aug 20091:36 pmRNSDirector/PDMR Shareholding
11th Aug 20095:45 pmRNSHolding(s) in Company
11th Aug 20095:15 pmRNSHolding(s) in Company
11th Aug 20094:19 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.